StockNews.com Lowers Agios Pharmaceuticals (NASDAQ:AGIO) to Sell

Agios Pharmaceuticals (NASDAQ:AGIOGet Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Monday.

Several other equities analysts have also issued reports on the company. Royal Bank of Canada upped their target price on Agios Pharmaceuticals from $44.00 to $53.00 and gave the company an “outperform” rating in a report on Tuesday, June 4th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $46.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. The Goldman Sachs Group upped their price objective on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a research note on Tuesday, June 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $50.67.

View Our Latest Stock Report on AGIO

Agios Pharmaceuticals Stock Up 0.0 %

AGIO stock traded up $0.01 during mid-day trading on Monday, reaching $45.23. 482,494 shares of the company traded hands, compared to its average volume of 836,032. The stock has a market cap of $2.57 billion, a price-to-earnings ratio of -7.16 and a beta of 0.77. Agios Pharmaceuticals has a fifty-two week low of $19.80 and a fifty-two week high of $49.06. The firm’s 50 day moving average price is $37.10 and its 200 day moving average price is $30.10.

Agios Pharmaceuticals (NASDAQ:AGIOGet Free Report) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.20. The company had revenue of $8.19 million during the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. Agios Pharmaceuticals’s quarterly revenue was up 46.0% on a year-over-year basis. During the same period in the prior year, the company posted ($1.47) earnings per share. On average, analysts anticipate that Agios Pharmaceuticals will post -2.68 EPS for the current fiscal year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,791 shares of the stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $27.55, for a total transaction of $214,642.05. Following the sale, the director now owns 137,396 shares in the company, valued at $3,785,259.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Farallon Capital Management LLC raised its position in shares of Agios Pharmaceuticals by 34.1% in the first quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company’s stock worth $163,469,000 after buying an additional 1,423,000 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Agios Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock worth $162,926,000 after buying an additional 44,583 shares in the last quarter. Armistice Capital LLC raised its position in shares of Agios Pharmaceuticals by 6.0% in the fourth quarter. Armistice Capital LLC now owns 3,524,000 shares of the biopharmaceutical company’s stock worth $78,479,000 after buying an additional 200,000 shares in the last quarter. Rock Springs Capital Management LP increased its stake in Agios Pharmaceuticals by 0.9% in the third quarter. Rock Springs Capital Management LP now owns 2,710,061 shares of the biopharmaceutical company’s stock valued at $67,074,000 after acquiring an additional 23,894 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Agios Pharmaceuticals by 5.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,596,764 shares of the biopharmaceutical company’s stock valued at $57,832,000 after acquiring an additional 137,873 shares during the last quarter.

About Agios Pharmaceuticals

(Get Free Report)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

See Also

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.